173 related articles for article (PubMed ID: 22861144)
1. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.
Langone A; Doria C; Greenstein S; Narayanan M; Ueda K; Sankari B; Pankewycz O; Shihab F; Chan L
Clin Transplant; 2013; 27(1):15-24. PubMed ID: 22861144
[TBL] [Abstract][Full Text] [Related]
2. Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry.
Doria C; Greenstein S; Narayanan M; Ueda K; Wiland A; McCague K; Sankari B; Chan L
Clin Transplant; 2012; 26(6):E602-11. PubMed ID: 23121178
[TBL] [Abstract][Full Text] [Related]
3. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
6. Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry.
Ueda K; McCague KM; Wiland A; Peddi VR
Ann Transplant; 2014 Feb; 19():84-92. PubMed ID: 24535029
[TBL] [Abstract][Full Text] [Related]
7. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.
Shihab FS; Olyaei A; Wiland A; McCague K; Norman DJ
Clin Transplant; 2014 Jul; 28(7):768-75. PubMed ID: 24754603
[TBL] [Abstract][Full Text] [Related]
9. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
Su VCh; Greanya ED; Ensom MH
Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
[TBL] [Abstract][Full Text] [Related]
10. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
Kamar N; Rostaing L; Cassuto E; Villemain F; Moal MC; Ladrière M; Barrou B; Ducloux D; Chaouche K; Quéré S; Di Giambattista F; Be F
Clin Nephrol; 2012 Feb; 77(2):126-36. PubMed ID: 22257543
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study.
Narayanan M; Pankewycz O; Shihab F; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Feb; 28(2):184-91. PubMed ID: 24372743
[TBL] [Abstract][Full Text] [Related]
13. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
[TBL] [Abstract][Full Text] [Related]
15. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience.
Rhu J; Lee KW; Park H; Park JB; Kim SJ; Choi GS
Ann Transplant; 2017 Nov; 22():707-718. PubMed ID: 29180612
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients.
Pons B; Delavenne X; Mehdi M; Maillard N; Sauron C; Berthoux F; Alamartine E; Basset T; Mariat C
Clin Nephrol; 2012 Jun; 77(6):425-31. PubMed ID: 22595383
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
19. Clinical Study of Standard- vs Reduced-Dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Kidney Transplantation: A Prospective Randomized Trial.
Bang JB; Oh CK; Ju MK; Kim SJ; Yu HC; Lee SH
Transplant Proc; 2020; 52(1):133-139. PubMed ID: 31898939
[TBL] [Abstract][Full Text] [Related]
20. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]